Glecaprevir/Pibrentasvir Approved to Treat All 6 Genotypes of HCV in Pediatric Patients
The FDA has approved Mavyret for the treatment of all 6 genotypes of hepatitis C virus in children 12 to 17 years old or weighing at least 45kg.
Hepatitis C
Glecaprevir + Pibrentasvir: Efficacious, Safe for HCV After Liver Transplantation
An 8- or 12-week regimen of glecaprevir and pibrentasvir is efficacious and safe in patients with HCV infection after liver transplantation.
Direct-Acting Antiviral Therapy and Recurrence of Hepatitis C-Related Hepatocellular Carcinoma
The impact of direct-acting antiviral therapy was investigated in a large cohort of patients in complete remission following treatment of hepatitis C-related HCC.
Benefits of Expanding HCV Treatment Outweigh Short-Term Costs for State Medicaid Programs
Findings suggest that states should consider revising their HCV treatment policies to include all individuals infected with HCV to achieve significant patient- and population-level benefits.
HCV Reinfection Rate a Concern Among MSM With HIV in Madrid
Data suggests that prevention strategies and frequent testing with HCV-RNA should be applied after sustained virologic response in MSM who engage in high-risk practices.
Pegylated Interferon α-2b Plus Ribavirin Effective for HCV Genotypes 2, 3
Investigators evaluated the real-life efficacy of pegylated interferon α-2b with ribavirin in treatment-naive patients with chronic genotypes 2 or 3 hepatitis C virus infection.
Ledipasvir/Sofosbuvir ± Ribavirin Effective, Safe in HCV With Advanced Liver Disease
A combination treatment of ledipasvir/sofosbuvir with or without ribavirin was an effective and tolerable treatment in patients with chronic hepatitis C and advanced liver disease before and after liver transplantation.
High Response Seen for All Hep C Treatment Models in Injection Drug Users
For people with HCV who inject drugs and receive opioid agonist therapy, receipt of HCV treatment is associated with high sustained virologic response.
Optimal Limit of Detection for a Point-of-Care HCV Viremia Test
Dataset of 66,640 individuals from 12 countries representative of 6 global regions confirmed that a test with a limit of detection of 1318 IU/mL would identify 97% of viremic HCV infections.
Heart, Lungs From Donor With Hepatitis C Can Be Transplanted Safely
Hearts and lungs from donors with hepatitis C viremia can be safely transplanted into patients without HCV.
Next post in Hepatitis
